Valuation: Guided Therapeutics Inc

Market Cap 2.9Cr 2.54Cr 2.36Cr 2.17Cr 4.1Cr 276.93Cr 4.19Cr 28Cr 11Cr 136.04Cr 11Cr 11Cr 470.41Cr P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 3.18Cr 2.8Cr 2.59Cr 2.38Cr 4.51Cr 304.43Cr 4.6Cr 31Cr 12Cr 149.55Cr 12Cr 12Cr 517.12Cr EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
63.48%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 70 06/03/2023
Chief Tech/Sci/R&D Officer 70 02/12/2010
Director TitleAgeSince
Director/Board Member 70 01/12/2016
Director/Board Member 76 10/04/2006
Chairman 67 01/10/2013
Change 5-day change 1-year change 3-year change Capi.($)
+0.28%+0.97%+21.54%+0.49% 20TCr
+0.08%-4.43%-20.49%+17.13% 14TCr
+0.56%+1.13%-2.29%-15.94% 14TCr
-0.27%-1.09%-56.73%-14.89% 6.65TCr
-0.46%-2.73%+17.60%-1.41% 5.31TCr
+2.80%+1.69%-22.83%-29.39% 4.41TCr
-0.19%+2.56%+8.73%+11.70% 3.79TCr
-0.85%-1.60%+5.76%+38.77% 3.7TCr
+0.94%-0.39%-13.07%-20.05% 2.94TCr
Average +0.41%-0.75%-6.87%-1.51% 8.32TCr
Weighted average by Cap. +0.44%-0.83%-3.67%-1.01%

Financials

2024 2025
Net sales 7T 6.15T 5.7T 5.24T 9.91T 7L 10.12T 67.99T 26.59T 3L 26.28T 25.71T 11.37L 8L 7L 6L 6L 10.86L 7.33Cr 11.09L 74.5L 29.14L 3.6Cr 28.8L 28.17L 12Cr
Net income -24.17L -21.23L -19.69L -18.1L -34.21L -23Cr -34.94L -2.35Cr -91.82L -11Cr -90.75L -88.77L -39Cr -31.96L -28.08L -26.03L -23.94L -45.23L -31Cr -46.2L -3.1Cr -1.21Cr -15Cr -1.2Cr -1.17Cr -52Cr
Net Debt 17.71L 15.56L 14.43L 13.27L 25.06L 17Cr 25.6L 1.72Cr 67.28L 8.32Cr 66.5L 65.05L 29Cr 28.76L 25.27L 23.43L 21.54L 40.7L 28Cr 41.58L 2.79Cr 1.09Cr 14Cr 1.08Cr 1.06Cr 47Cr
Logo Guided Therapeutics Inc
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
-